SecBot SecBot
SECBOTREPLAY Home › Report › COR

COR · Segment restructuring disclosed

Cencora, Inc. · 8-K filed Nov 4, 2026 at 09:25 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Nov 4, 2026 at 09:25 ET

Cencora filed an 8-K to disclose a restructuring of its operating model and a new reportable segment structure effective Q1 FY2027. The filing includes unaudited revised segment revenue and operating income data for FY2025 and FY2026 under the new segments: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. This is a routine disclosure of a structural change with no new financial guidance or material impact on overall results.

  • Cencora restructured its operating model and reorganized business components within U.S. Healthcare Solutions and International Healthcare Solutions reportable segments.
  • New reporting structure effective Q1 FY2027: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other.
  • Other segment includes businesses under strategic review: MWI Animal Health, Profarma, and other components of PharmaLex.
  • FY2026 total revenue was $337.4 billion, up 5.0% from FY2025 total revenue of $321.3 billion.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access